UNSPSC 51202603: Everolimus

This classification denotes a mtor inhibitor and immunosuppressant with the molecular formula C53H83NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 9HW64Q8G6G, chemically known as rapamycin, 42-o-(2-hydroxyethyl)- but more generally known as everolimus, which bears US NIH Compound Identifier 6442177. European Medicines Agency schedules Everolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02065MIG.

UNSPSC 51202603 Everolimus (Commodity) shows no relevant recent state and local procurement activity. The two opportunities present in the recent-opportunities block—a piggyback pharmaceutical warehouse contract awarded by the Illinois Department of Public Health for Doxycycline Hyclate and Ciprofloxacin Hydrochloride, and a Seminole County, Florida IFB for Naloxone and drug deactivation systems—are for distinct pharmaceutical products unrelated to Everolimus, a targeted cancer immunosuppressant. The Illinois contract, completed in August 2026, was awarded to Chartwell Rx LLC for $2.999 million over three years; the Seminole County solicitation, posted in June 2026 with a July 26 response deadline, sought annual volumes of 1,900 units of Naloxone and 800 deactivation systems. Neither opportunity solicits Everolimus or indicates procurement patterns under this Commodity code.

State and local governments do not appear to be active buyers of Everolimus through open competitive procurement channels at this time. The code may see activity through specialty pharmaceutical contracts, healthcare system formularies, or cooperative purchasing agreements not represented in recent posted solicitations, but no open RFP, RFQ, IFB, or ITB activity for Everolimus is currently visible. Firms pursuing this code should monitor cooperative pharmaceutical purchasing consortia and state health department contract vehicles for formulary additions or statewide framework agreements rather than expect frequent standalone solicitations.